Roger Yang, MD, began his Vasculitis Clinical Research Consortium (VCRC)-Vasculitis Foundation (VF) Fellowship in September 2022. Dr. Yang’s training through the Penn Vasculitis Center at the University of Pennsylvania will focus on both clinical care of patients with all forms of vasculitis and research on the diseases. As vasculitis may…...
Amgen Successfully Completes Acquisition of ChemoCentryx
TAVNEOS® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif., (Oct. 20, 2022) – Amgen (NASDAQ: AMGN) today announced that it has successfully completed its previously announced acquisition of ChemoCentryx, Inc. (NASDAQ: CCXI), a biopharmaceutical company focused on orally administered therapeutics to treat…...
